Print Page     Close Window     

SEC Filings

424B3
BIOTIME INC filed this Form 424B3 on 02/04/2019
Entire Document
 
 

 

If you are an Asterias stockholder and, at any time, you no longer wish to participate in householding and would prefer to receive a separate joint proxy statement/prospectus, or if you are receiving multiple copies of this joint proxy statement/prospectus and wish to receive only one, please call Advantage Proxy, the proxy solicitor for Asterias, toll-free at 877-870-8565 or international at +206-870-8565 or write to Advantage Proxy at P.O. Box 13581, Des Moines, WA 98198. If you are an Asterias stockholder and hold shares in street name, you may request a separate copy by calling Investor Relations at 510 456-3892, or by writing to Investor Relations, Asterias Biotherapeutics, Inc. 6300 Dumbarton Circle, Fremont, California, 94555.

 

For future annual or special meetings, BioTime shareholders and Asterias stockholders may request separate voting materials, or request that BioTime or Asterias, respectively, send only one set of proxy materials by contacting Investor Relations at the above phone number or address.

 

WHERE YOU CAN FIND MORE INFORMATION

 

BioTime and Asterias file annual, quarterly and special reports, proxy statements and other information with the SEC under the Exchange Act. You may read and copy any of this information at the SEC’s Public Reference Room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room. The SEC also maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers, including BioTime and Asterias, who file electronically with the SEC. The address of that site is www.sec.gov.

 

Investors may also consult BioTime’s or Asterias’ website for more information concerning the Merger described in this joint proxy statement/prospectus. BioTime’s website is www.biotimeinc.com. Asterias’ website is www.asteriasbiotherapeutics.com. Information included on either website is not incorporated by reference into this joint proxy statement/prospectus. The information contained on the websites of BioTime, Asterias and the SEC (except for the filings described below) is expressly not incorporated by reference into this joint proxy statement/prospectus.

 

BioTime has filed with the SEC a Registration Statement of which this joint proxy statement/prospectus forms a part. The registration statement registers the BioTime Common Shares to be issued to Asterias stockholders in connection with the Merger. The registration statement, including the attached exhibits and schedules, contains additional relevant information about BioTime Common Shares. The rules and regulations of the SEC allow BioTime and Asterias to omit certain information included in the registration statement from this joint proxy statement/prospectus.

 

In addition, the SEC allows BioTime and Asterias to disclose important information to you by referring you to other documents filed separately with the SEC. This information is considered to be a part of this joint proxy statement/prospectus, except for any information that is superseded by information included directly in this joint proxy statement/prospectus.

 

This joint proxy statement/prospectus incorporates by reference the documents listed below that BioTime has previously filed or will file with the SEC (other than information furnished pursuant to Item 2.02 or Item 7.01 of a Current Report on Form 8-K). They contain important information about BioTime, its financial condition and other matters.

 

Annual Report on Form 10-K for the fiscal year ended December 31, 2017.
   
Proxy Statement on Schedule 14A filed March 29, 2018.
   
Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2018, June 30, 2018 and September 30, 2018.
   

Current Reports on Form 8-K dated September 18, 2018, October 5, 2018, November 8, 2018, December 20, 2018 and January 4, 2019 (other than the portions of those documents deemed to be furnished and not filed).

   
The description of BioTime Common Shares on Form 8-A (File No. 001-12830) filed with SEC on October 26, 2009, as amended.

 

171

© Copyright BioTime, Inc.